Sanofi, Regeneron say late-stage Dupixent trials show positive results
PARIS: Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues.
Sanofi and Regeneron said in a joint statement that two pivotal Phase 3 placebo-controlled trials evaluating Dupixent (dupilumab), in adults with inadequately controlled chronic rhinosinusitis with nasal polyps, had met all primary and secondary endpoints.
The U.S. Food & Drug Administration regulator is expected to approve Dupixent for asthma treatment before the year-end.
Sanofi and Regeneron said in a joint statement that two pivotal Phase 3 placebo-controlled trials evaluating Dupixent (dupilumab), in adults with inadequately controlled chronic rhinosinusitis with nasal polyps, had met all primary and secondary endpoints.
The U.S. Food & Drug Administration regulator is expected to approve Dupixent for asthma treatment before the year-end.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd